Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Verizon Communications Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Verizon Communications Inc trades at $49.77 (market cap $209.44B). The key difference: Verizon Communications Inc is the larger of the two by market cap, and Verizon Communications Inc pays a 5.61% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | VZ | |
|---|---|---|
Market Cap | $134.06B | $209.44B |
Sector | Health | Media |
52-Week High | $557.96 | $51.38 |
52-Week Low | $376.62 | $38.40 |
Enterprise Value | $128.18B | $396.15B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock offers a 5%+ dividend yield, supported by strong cash flow and a P/E of 13.13. Recent news highlights growth in broadband and AI infrastructure, including a multi-billion dollar fiber deal with Corning.
Outlook is positive with cost discipline and shareholder returns, but risks include high debt and competitive pressures. Analysts are mixed with a $49.69 consensus target, slightly below current price, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
